2019
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial
Patel RB, Alenezi F, Sun JL, Alhanti B, Vaduganathan M, Oh JK, Redfield MM, Butler J, Hernandez AF, Velazquez EJ, Shah SJ. Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. Journal Of Cardiac Failure 2019, 26: 270-275. PMID: 31857197, PMCID: PMC7078046, DOI: 10.1016/j.cardfail.2019.12.001.Peer-Reviewed Original ResearchConceptsLA reservoir strainLA myopathyHeart failureNT-proBNPEjection fractionLA reservoirReservoir strainLA strainN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideAtrial mechanical dysfunctionEjection Fraction trialLA contractile strainLower LA reservoirJugular venous pressurePoor clinical outcomePhosphodiesterase-5 inhibitionAssociation of LAAtrial myopathyBaseline echocardiogramRELAX trialNeurohormonal activationExercise capacityVenous pressureClinical outcomes
2017
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial
DeVore AD, McNulty S, Alenezi F, Ersboll M, Vader JM, Oh JK, Lin G, Redfield MM, Lewis G, Semigran MJ, Anstrom KJ, Hernandez AF, Velazquez EJ. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial. European Journal Of Heart Failure 2017, 19: 893-900. PMID: 28194841, PMCID: PMC5511088, DOI: 10.1002/ejhf.754.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersDouble-Blind MethodEchocardiographyExercise ToleranceFemaleFollow-Up StudiesHeart Failure, SystolicHeart VentriclesHumansMaleMiddle AgedMyocardial ContractionNatriuretic Peptide, BrainOxygen ConsumptionPeptide FragmentsProcollagenQuality of LifeRetrospective StudiesStroke VolumeTime FactorsVentricular Function, LeftConceptsLV global longitudinal strainGlobal longitudinal strainImpaired LV global longitudinal strainVentricular global longitudinal strainEjection fractionQuality of lifeRELAX trialExercise capacityHeart failureN-terminal pro-brain natriuretic peptideLeft ventricular global longitudinal strainWorse LV global longitudinal strainLog-transformed NT-proBNPPro-brain natriuretic peptideNormal LV ejection fractionLongitudinal strainHeart failure scoreLV ejection fractionPeak oxygen consumptionHFpEF patientsMinnesota LivingDiastolic dysfunctionNT-proBNPSystolic dysfunctionClinical characteristics
2015
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal Of Medicine 2015, 373: 2314-2324. PMID: 26549714, PMCID: PMC4712067, DOI: 10.1056/nejmoa1510774.Peer-Reviewed Original ResearchConceptsHeart failureEjection fractionIsosorbide mononitratePlacebo groupDose regimensWalk distanceLife scoresN-terminal pro-brain natriuretic peptidePro-brain natriuretic peptideEnd pointSignificant between-group differencesIsosorbide mononitrate groupLow daily activityNT-proBNP levelsPrimary end pointSecondary end pointsSubmaximal exercise capacityDose-escalation regimenHours of activityActivity levelsBetween-group differencesDaily activity levelsDaily activitiesActivity toleranceExercise capacity
2014
Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy An Analysis From the STICH Trial (Surgical Treatment for Ischemic Heart Failure)
Stewart RA, Szalewska D, She L, Lee KL, Drazner MH, Lubiszewska B, Kosevic D, Ruengsakulrach P, Nicolau JC, Coutu B, Choudhary SK, Mark DB, Cleland JG, Piña IL, Velazquez EJ, Rynkiewicz A, White H. Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy An Analysis From the STICH Trial (Surgical Treatment for Ischemic Heart Failure). JACC Heart Failure 2014, 2: 335-343. PMID: 25023813, PMCID: PMC4127151, DOI: 10.1016/j.jchf.2014.02.009.Peer-Reviewed Original ResearchConceptsCoronary artery bypass graft surgeryIschemic left ventricular dysfunctionLeft ventricular dysfunctionArtery bypass graft surgeryBypass graft surgeryPoor exercise capacityExercise capacityMedical therapyVentricular dysfunctionSTICH trialGraft surgeryBetter exercise capacityWalk testMedical managementPrognostic significanceTreatment allocationPhysical activityPatientsEarly riskHigh mortalityMortalityTherapyDysfunctionSurgeryTrials
2013
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor C, Felker GM, Goldsmith SR, Bart B, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, Trial F. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2013, 309: 1268-1277. PMID: 23478662, PMCID: PMC3835156, DOI: 10.1001/jama.2013.2024.Peer-Reviewed Original ResearchConceptsPeak oxygen consumptionPhosphodiesterase-5 inhibitionExercise capacityWalk distanceEjection fractionHeart failureClinical statusPlacebo patientsAdverse eventsClinical trialsFilling pressureN-terminal brain-type natriuretic peptideElevated left ventricular filling pressureMedian peak oxygen consumptionPulmonary artery systolic pressureLeft ventricular filling pressureBrain-type natriuretic peptidePhosphodiesterase-5 inhibitor sildenafilEnd pointOxygen consumptionPrimary end pointSecondary end pointsVentricular filling pressureWeek 24 dataWeeks of therapy